Ceribell, Inc. (CBLL) AI Stock Analysis

• Market Cap: $449.13M
• Dividend Yield: N/A
• Average Volume (3M): 313.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 281
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.38
• Shares Outstanding: 36,663,967
• 10 Day Avg. Volume: 304,852
• 30 Day Avg. Volume: 313,621
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: 6.77
• Enterprise Value/Gross Profit: 7.71
• Enterprise Value/Ebitda: -11.35
• 1Y Price Target: $25.80
• Price Target Upside: 110.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 52 Neutral
• Price Target: $13.00 ▲(6.12% Upside)

Ceribell, Inc. shows strong revenue growth and improved financial position, but faces challenges with profitability, cash flow management, and legal issues. The stock is technically oversold, and valuation metrics suggest caution. The positive earnings call outlook is a significant strength, but operational inefficiencies and external financing reliance are key risks.

Positive Factors

Revenue Growth

Strong revenue growth indicates increasing demand for Ceribell's products, suggesting successful market penetration and product adoption.

High Gross Margin

High gross margins reflect efficient cost management and pricing power, supporting long-term profitability potential despite current losses.

Commercial Expansion

Strategic expansion into new territories can drive future revenue growth and strengthen market presence, enhancing competitive positioning.

Negative Factors

Increased Operating Expenses

Rising operating expenses can pressure margins and profitability, potentially hindering financial performance if not managed effectively.

Net Loss

Ongoing net losses highlight the challenge of achieving profitability, which may impact investor confidence and necessitate further financing.

Legal Challenges

Legal disputes can divert resources and focus, potentially affecting operational efficiency and financial stability over the medium term.

Ceribell, Inc. Business Overview & Revenue Model

Company Description

Ceribell, Inc. (CBLL) is a medical technology company that specializes in developing and providing rapid electroencephalography (EEG) solutions for the diagnosis and management of neurological conditions. The company focuses on creating innovative, user-friendly EEG systems that improve the speed and accuracy of diagnosing conditions such as seizures in emergency and critical care settings. Ceribell's core product is the Ceribell EEG system, designed to be portable and easy to use, enabling healthcare professionals to rapidly conduct EEGs at the point of care.

How the Company Makes Money

Ceribell, Inc. generates revenue primarily through the sale of its EEG systems to hospitals and medical institutions. The company's revenue model includes the direct sale of its EEG hardware, as well as recurring revenue from the consumables and accessories required for the operation of these systems. Additionally, Ceribell may offer service contracts and training for healthcare providers to ensure proper usage and maintenance of their equipment. Significant partnerships with hospitals, healthcare systems, and potentially government health bodies could contribute to the company's earnings by facilitating broader adoption of their technology.

Ceribell, Inc. Financial Statement Overview

Summary

Ceribell, Inc. demonstrates strong revenue growth and improved equity position, but struggles with profitability and cash flow management. The company shows high gross margins but faces operational inefficiencies and relies on external financing.

Income Statement

Ceribell, Inc. shows solid revenue growth of 44.7% from 2023 to 2024, highlighting strong demand for their products. However, the company is operating at a loss with a negative net profit margin, and EBIT and EBITDA margins indicate inefficiencies. Gross profit margins are strong at approximately 86.7% for 2024, signifying good production cost management but are overshadowed by the high operating expenses.

Balance Sheet

The company's equity has significantly improved from negative to a strong positive position in 2024, indicating strong financial backing or recent capital infusion. The debt-to-equity ratio is low due to high equity, showcasing low leverage risk. However, the equity ratio is high at 84.8%, reflecting a stable asset base primarily funded by equity.

Cash Flow

Ceribell's free cash flow is negative but has shown improvement from 2023. The high operating cash outflows are concerning, relative to the negative net income, indicating cash management issues. A significant financing cash flow in 2024 suggests reliance on external funding to cover operational deficits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	77.42M	65.44M	45.23M	25.92M
Gross Profit	67.94M	56.75M	38.16M	21.49M
EBITDA	-46.17M	-37.71M	-26.51M	-35.06M
Net Income	-49.41M	-40.45M	-29.46M	-37.16M
Balance Sheet
Total Assets	207.69M	225.41M	58.92M	86.46M
Cash, Cash Equivalents and Short-Term Investments	177.43M	194.37M	34.49M	68.23M
Total Debt	21.55M	21.96M	14.20M	18.22M
Total Liabilities	35.53M	34.25M	171.17M	172.86M
Stockholders Equity	172.16M	191.16M	-112.25M	-86.40M
Cash Flow
Free Cash Flow	-38.60M	-36.38M	-30.14M	-32.52M
Operating Cash Flow	-37.45M	-35.04M	-29.16M	-32.00M
Investing Cash Flow	-137.61M	-1.60M	-1.76M	-1.40M
Financing Cash Flow	190.85M	196.52M	-2.82M	49.80M

Ceribell, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBLL, the sentiment is Neutral. The current price of 12.25 is above the 20-day moving average (MA) of 11.82, below the 50-day MA of 13.15, and below the 200-day MA of 18.79, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 49.79 is Neutral, neither overbought nor oversold. The STOCH value of 72.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CBLL.

Ceribell, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRMD	80 Outperform	897.01M	43.74	22.15%	0.94%	11.73%	10.27%
AXGN	69 Neutral	791.42M	-162.72	-4.15%	―	17.17%	72.68%
BFLY	54 Neutral	465.72M	-6.62	-42.94%	―	23.13%	46.62%
CBLL	52 Neutral	$449.13M	―	26.25%	―	―	―
AVNS	51 Neutral	552.65M	-1.18	-59.67%	―	1.48%	-6091.13%
RXST	51 Neutral	385.02M	-11.79	-11.60%	―	27.68%	20.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Ceribell, Inc. Corporate Events

Ceribell Files Patent Infringement Complaints Against Natus

On July 7, 2025, Ceribell, Inc. announced it filed complaints against Natus Medical Incorporated with the U.S. International Trade Commission and the U.S. District Court for the District of Delaware, alleging patent infringement and unfair competition related to its EEG headband and electrode design. Ceribell seeks to protect its intellectual property and maintain fair competition, requesting an investigation and exclusion order to prevent the importation of infringing Natus products into the U.S., highlighting its commitment to innovation in point-of-care EEG technology.

The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Ceribell Extends Exclusive License with Stanford University

Ceribell, Inc. and Stanford University have amended their exclusive agreement, initially effective from June 15, 2015, to extend the exclusivity of Ceribell’s license for certain portable brain wave activity devices. On June 12, 2025, Ceribell exercised an option to extend this exclusivity by paying a $250,000 fee, which impacts the company’s operations by securing continued access to patented technology.

The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Ceribell, Inc. Announces Results of Annual Meeting

On June 10, 2025, Ceribell, Inc. held its Annual Meeting of Stockholders, where two key proposals were voted on. The stockholders elected Juliet Tammenoms Bakker and Lucian Iancovici, M.D. as Class I directors to serve until the 2028 meeting, and approved the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.